세계의 소아 성장 호르몬 결핍증 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)

Pediatric growth hormone deficiency is an uncommon condition that primarily affects children. Pediatric growth hormones, which are generated by the pituitary gland, are crucial for children's growth. Throughout life, growth hormones play a vital role in metabolic and physiological processes. When the pituitary gland or the hypothalamus is damaged, the quantity of growth hormone generated is decreased, resulting in Pediatric Growth Hormone Deficiency, which results in a slower pace of growth and a reduction in height in the affected child.

MARKET DYNAMICS:

The rising prevalence of pituitary gland tumours, endocrine problems, genetic disorders, and family-related growth hormone deficiency is likely to increase the pediatric growth hormone deficiency market. The progress of medical advancements, more government subsidies, and rising activities by several organizations to raise awareness of the problem are the factors that will drive the pediatric growth hormone deficiency market forward. In addition, the rising number of pediatric diagnostic projects and campaigns will increase the pediatric growth hormone deficiency market. However, the high cost of pediatric growth hormone deficiency injections, side effects related to hormone treatment, and insufficient awareness of growth hormone deficiency are the primary factors predicted to hinder the market growth of pediatric growth hormone deficiency.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pediatric growth hormone deficiency. The growth and trends of pediatric growth hormone deficiency industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pediatric growth hormone deficiency market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Congenital GH Deficiency
• Acquired GH Deficiency
• Idiopathic GH Deficiency

By Product

• Powder
• Solvent

By Application

• Growth Hormone Deficiency
• Idiopathic Short Stature
• Turner Syndrome
• Small For Gestational Age
• Prader-Willi Syndrome
• Others

By Drug

• Genotropin
• Humatrope
• Norditropin Flexpro
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Pediatric Growth Hormone Deficiency market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pediatric growth hormone deficiency market include Novo Nordisk A/S, Eli Lily and Company, Novartis AG, Merck KGaA, Pfizer Inc., Ferring B.V, Genentech, BioParteners GmbH, LG Chem Ltd., Ipsen Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PEDIATRIC GROWTH HORMONE DEFICIENCY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Product
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By Drug
  • 3.7.5 Market Attractiveness Analysis By Distribution Channel
  • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET ANALYSIS BY TYPE

• 6.1 Overview by Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Type
• 6.4 Congenital GH Deficiency Historic and Forecast Sales by Regions
• 6.5 Acquired GH Deficiency Historic and Forecast Sales by Regions
• 6.6 Idiopathic GH Deficiency Historic and Forecast Sales by Regions

7 . GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET ANALYSIS BY PRODUCT

• 7.1 Overview by Product
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Product
• 7.4 Powder Historic and Forecast Sales by Regions
• 7.5 Solvent Historic and Forecast Sales by Regions

8 . GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET ANALYSIS BY APPLICATION

• 8.1 Overview by Application
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Application
• 8.4 Growth Hormone Deficiency Historic and Forecast Sales by Regions
• 8.5 Idiopathic Short Stature Historic and Forecast Sales by Regions
• 8.6 Turner Syndrome Historic and Forecast Sales by Regions
• 8.7 Small For Gestational Age Historic and Forecast Sales by Regions
• 8.8 Prader-Willi Syndrome Historic and Forecast Sales by Regions
• 8.9 Others Historic and Forecast Sales by Regions

9 . GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET ANALYSIS BY DRUG

• 9.1 Overview by Drug
• 9.2 Historical and Forecast Data
• 9.3 Analysis by Drug
• 9.4 Genotropin Historic and Forecast Sales by Regions
• 9.5 Humatrope Historic and Forecast Sales by Regions
• 9.6 Norditropin FlexPro Historic and Forecast Sales by Regions
• 9.7 Others Historic and Forecast Sales by Regions

10 . GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 10.1 Overview by Distribution Channel
• 10.2 Historical and Forecast Data
• 10.3 Analysis by Distribution Channel
• 10.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 10.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 10.6 Online Pharmacies Historic and Forecast Sales by Regions
• 10.7 Others Historic and Forecast Sales by Regions

11 . GLOBAL PEDIATRIC GROWTH HORMONE DEFICIENCY MARKET ANALYSIS BY GEOGRAPHY

• 11.1. Top Company Share Analysis
• 11.2. Introduction
• 11.3. North America Sales Analysis
  • 11.3.1. Overview, Historic and Forecast Sales Analysis
  • 11.3.2. North America By Segment Sales Analysis
  • 11.3.3. North America By Country Sales Analysis
  • 11.3.4. United State Sales Analysis
  • 11.3.5. Canada Sales Analysis
  • 11.3.6. Mexico Sales Analysis
• 11.4. Europe Sales Analysis
  • 11.4.1. Overview, Historic and Forecast Sales Analysis
  • 11.4.2. Europe by Segment Sales Analysis
  • 11.4.3. Europe by Country Sales Analysis
  • 11.4.4. United Kingdom Sales Analysis
  • 11.4.5. France Sales Analysis
  • 11.4.6. Germany Sales Analysis
  • 11.4.7. Italy Sales Analysis
  • 11.4.8. Russia Sales Analysis
  • 11.4.9. Rest Of Europe Sales Analysis
• 11.5. Asia Pacific Sales Analysis
  • 11.5.1. Overview, Historic and Forecast Sales Analysis
  • 11.5.2. Asia Pacific by Segment Sales Analysis
  • 11.5.3. Asia Pacific by Country Sales Analysis
  • 11.5.4. China Sales Analysis
  • 11.5.5. India Sales Analysis
  • 11.5.6. Japan Sales Analysis
  • 11.5.7. South Korea Sales Analysis
  • 11.5.8. Australia Sales Analysis
  • 11.5.9. Rest Of Asia Pacific Sales Analysis
• 11.6. Latin America Sales Analysis
  • 11.6.1. Overview, Historic and Forecast Sales Analysis
  • 11.6.2. Latin America by Segment Sales Analysis
  • 11.6.3. Latin America by Country Sales Analysis
  • 11.6.4. Brazil Sales Analysis
  • 11.6.5. Argentina Sales Analysis
  • 11.6.6. Peru Sales Analysis
  • 11.6.7. Chile Sales Analysis
  • 11.6.8. Rest of Latin America Sales Analysis
• 11.7. Middle East & Africa Sales Analysis
  • 11.7.1. Overview, Historic and Forecast Sales Analysis
  • 11.7.2. Middle East & Africa by Segment Sales Analysis
  • 11.7.3. Middle East & Africa by Country Sales Analysis
  • 11.7.4. Saudi Arabia Sales Analysis
  • 11.7.5. UAE Sales Analysis
  • 11.7.6. Israel Sales Analysis
  • 11.7.7. South Africa Sales Analysis
  • 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE PEDIATRIC GROWTH HORMONE DEFICIENCY COMPANIES

• 12.1. Pediatric Growth Hormone Deficiency Market Competition
• 12.2. Partnership/Collaboration/Agreement
• 12.3. Merger And Acquisitions
• 12.4. New Product Launch
• 12.5. Other Developments

13 . COMPANY PROFILES OF PEDIATRIC GROWTH HORMONE DEFICIENCY INDUSTRY

• 13.1. Company Share Analysis
• 13.2. Market Concentration Rate
• 13.3. Novo Nordisk A/S
  • 13.3.1. Company Overview
  • 13.3.2. Company Revenue
  • 13.3.3. Products
  • 13.3.4. Recent Developments
• 13.4. Eli Lily and Company
  • 13.4.1. Company Overview
  • 13.4.2. Company Revenue
  • 13.4.3. Products
  • 13.4.4. Recent Developments
• 13.5. Novartis AG
  • 13.5.1. Company Overview
  • 13.5.2. Company Revenue
  • 13.5.3. Products
  • 13.5.4. Recent Developments
• 13.6. Merck KGaA
  • 13.6.1. Company Overview
  • 13.6.2. Company Revenue
  • 13.6.3. Products
  • 13.6.4. Recent Developments
• 13.7. Pfizer Inc.
  • 13.7.1. Company Overview
  • 13.7.2. Company Revenue
  • 13.7.3. Products
  • 13.7.4. Recent Developments
• 13.8. Ferring B.V
  • 13.8.1. Company Overview
  • 13.8.2. Company Revenue
  • 13.8.3. Products
  • 13.8.4. Recent Developments
• 13.9. Genentech
  • 13.9.1. Company Overview
  • 13.9.2. Company Revenue
  • 13.9.3. Products
  • 13.9.4. Recent Developments
• 13.10. BioParteners GmbH
  • 13.10.1. Company Overview
  • 13.10.2. Company Revenue
  • 13.10.3. Products
  • 13.10.4. Recent Developments
• 13.11. LG Chem Ltd.
  • 13.11.1. Company Overview
  • 13.11.2. Company Revenue
  • 13.11.3. Products
  • 13.11.4. Recent Developments
• 13.12. Ipsen Pharma
  • 13.12.1. Company Overview
  • 13.12.2. Company Revenue
  • 13.12.3. Products
  • 13.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies